Combining SYNC-T Immunotherapy with SV102 for Metastatic Prostate Cancer

• Limited impact of immunotherapy on metastatic prostate cancer
• Key need to combine multiple immunotherapy mechanisms to overcome tumor resistance to the immune system
• Using a local-regional approach SYNC-T therapy allows multiple mechanisms to be combined without severe autoimmunity

Speakers:

Charles Link

Executive Chairman & Chief Innovation Officer

Syncromune